Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness.

[1]  James G. Krueger,et al.  Pathogenesis and therapy of psoriasis , 2007, Nature.

[2]  K. Meiri.  Lipid rafts and regulation of the cytoskeleton during T cell activation , 2005, Philosophical Transactions of the Royal Society B: Biological Sciences.

[3]  J. Krueger,et al.  Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series , 2005, BMC dermatology.

[4]  Mark J. Miller,et al.  The c-SMAC , 2005, The Journal of cell biology.

[5]  T. Kinashi,et al.  Intracellular signalling controlling integrin activation in lymphocytes , 2005, Nature Reviews Immunology.

[6]  S. Pippig,et al.  TISSUE DISTRIBUTION AND RECEPTOR-MEDIATED CLEARANCE OF ANTI-CD11A ANTIBODY IN MICE , 2005, Drug Metabolism and Disposition.

[7]  D. Morgan,et al.  The Role of Intercellular Adhesion Molecule-1/LFA-1 Interactions in the Generation of Tumor-Specific CD8+ T Cell Responses1 , 2005, The Journal of Immunology.

[8]  A. Gottlieb,et al.  Pharmacokinetics and Pharmacodynamics of Multiple Weekly Subcutaneous Efalizumab Doses in Patients With Plaque Psoriasis , 2005, Journal of clinical pharmacology.

[9]  Y. Vugmeyster,et al.  Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. , 2004, Clinical immunology.

[10]  K. Wittkowski.  Effects and non‐effects of paired identical observations in comparing proportions with binary matched‐pairs data. By A. Agresti and Y. Min. Statistics in Medicine 2004; 23:65–75 , 2004, Statistics in medicine.

[11]  A. Rao,et al.  T-cell anergy. , 2004, Current opinion in immunology.

[12]  Alan Agresti,et al.  Effects and non‐effects of paired identical observations in comparing proportions with binary matched‐pairs data , 2004, Statistics in medicine.

[13]  N. Hogg,et al.  T-cell integrins: more than just sticking points , 2003, Journal of Cell Science.

[14]  M. Lebwohl,et al.  A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. , 2003, The New England journal of medicine.

[15]  Mark M Davis,et al.  Continuous T cell receptor signaling required for synapse maintenance and full effector potential , 2003, Nature Immunology.

[16]  J. Hunyadi,et al.  Elevated rate of Thelper1 (TH1) lymphocytes and serum IFN-γ levels in psoriatic patients , 2003 .

[17]  L. Appleman,et al.  T cell anergy and costimulation , 2003, Immunological reviews.

[18]  G. Pinkus,et al.  Increased CCR4 expression in cutaneous T cell lymphoma. , 2002, The Journal of investigative dermatology.

[19]  A. Gottlieb,et al.  Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. , 2002, Archives of dermatology.

[20]  G. Zimmerman,et al.  Leukocyte adhesion deficiency syndromes: adhesion and tethering defects involving beta 2 integrins and selectin ligands. , 2002, Current opinion in hematology.

[21]  N. Klein,et al.  Characterization of four CD18 mutants in leucocyte adhesion deficient (LAD) patients with differential capacities to support expression and function of the CD11/CD18 integrins LFA‐1, Mac‐1 and p150,95 , 2001, Clinical and experimental immunology.

[22]  P A Bates,et al.  Genetic analysis of integrin function in man: LAD-1 and other syndromes. , 2000, Matrix biology : journal of the International Society for Matrix Biology.

[23]  A. Khanna,et al.  Cyclosporine induces the expression of the cyclin inhibitor p21. , 1999, Transplantation.

[24]  H. Dumon,et al.  Alteration of intracellular calcium flux and impairment of nuclear factor-AT translocation in T cells during acute Toxoplasma gondii infection in mice. , 1998, Journal of immunology.

[25]  L. Presta,et al.  Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. , 1996, Journal of immunology.

[26]  K. Amano,et al.  Induction of tolerance in murine autoimmune diabetes by transient blockade of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 pathway. , 1996, Journal of immunology.

[27]  M. Miyasaka,et al.  Short term treatment with soluble neuroantigen and anti-CD11a (LFA-1) protects rats against autoimmune encephalomyelitis: treatment abrogates autoimmune disease but not autoimmunity. , 1996, Journal of Immunology.

[28]  N. Hogg,et al.  T cell adhesion to intercellular adhesion molecule-1 (ICAM-1) is controlled by cell spreading and the activation of integrin LFA-1. , 1996, Journal of immunology.

[29]  C. Figdor,et al.  Critical amino acids in the lymphocyte function-associated antigen-1 I domain mediate intercellular adhesion molecule 3 binding and immune function , 1996, The Journal of experimental medicine.

[30]  Y. Ron,et al.  Bothanti-CD11a(LFA-l) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis , 1995, Journal of Neuroimmunology.

[31]  T. Carlos,et al.  Leukocyte-endothelial adhesion molecules. , 1994, Blood.

[32]  G. Zlabinger,et al.  Specific down-regulation of proliferative T cell alloresponsiveness by interference with CD2/LFA-3 and LFA-1/ICAM-1 in vitro. , 1994, Journal of immunology.

[33]  R. Schwartz.  T cell anergy. , 2003, Annual review of immunology.

[34]  S. Habu,et al.  Inhibition of inflammatory liver injury by a monoclonal antibody against lymphocyte function-associated antigen-1. , 1993, Journal of immunology.

[35]  S. Kanner,et al.  Beta 2-integrin LFA-1 signaling through phospholipase C-gamma 1 activation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[36]  E. Puré,et al.  Reduced contact sensitivity reactions in mice treated with monoclonal antibodies to leukocyte function-associated molecule-1 and intercellular adhesion molecule-1. , 1993, Journal of immunology.

[37]  C. June,et al.  Costimulation of T cell receptor/CD3-mediated activation of resting human CD4+ T cells by leukocyte function-associated antigen-1 ligand intercellular cell adhesion molecule-1 involves prolonged inositol phospholipid hydrolysis and sustained increase of intracellular Ca2+ levels. , 1992, Journal of immunology.

[38]  M. Isobe,et al.  Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. , 1992, Science.

[39]  H. Grey,et al.  Analysis of T cell stimulation by superantigen plus major histocompatibility complex class II molecules or by CD3 monoclonal antibody: costimulation by purified adhesion ligands VCAM-1, ICAM-1, but not ELAM-1 , 1991, The Journal of experimental medicine.

[40]  K. Horgan,et al.  The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. , 1990, Journal of immunology.

[41]  R. Schwartz,et al.  A cell culture model for T lymphocyte clonal anergy. , 1990, Science.

[42]  J. Ferrara,et al.  Evidence that anti-asialo GM1 in vivo improves engraftment of T cell-depleted bone marrow in hybrid recipients. , 1990, Transplantation.

[43]  S. Cobbold,et al.  Mechanisms of monoclonal antibody‐facilitated tolerance induction: a possible role for the CD4 (L3T4) and CD11a (LFA‐1) molecules in self‐non‐self discrimination , 1988, European journal of immunology.

[44]  A. Fischer,et al.  Role of the LFA-1 molecule in cellular interactions required for antibody production in humans. , 1986, Journal of immunology.